Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However, despite initial tumor control, most patients suffer from locoregional relapse and/or metastatic disease...
Resources
Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma
Purpose: Local tumor growth is a major cause of morbidity and mortality in nearly 30% of patients with pancreatic ductal adenocarcinoma (PDAC). Radiotherapy (RT) is commonly used for local disease control in PDAC, but efficacy is limited. We studied the impact of...
Xbridge connectivity showcased at degro 2016
Xstrahl (Booth B29) will showcase the next generation in 3rd party connectivity for Xstrahl systems at this year’s Deutschen Gesellschaft für Radioonkologie e.V. (DEGRO) in Mannheim, Germany from 16th – 19th June. XBridge offers Xstrahl users the ability to communicate with 3rd party clinical information systems, enabling data import of patient demographics and export of treatment information, ensuring traceability throughout a patient’s treatment.
Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
We proposed to exploit hypoxia-inducible factor (HIF)-1alpha overexpression in prostate tumours and use this transcriptional machinery to control the expression of the suicide gene cytosine deaminase (CD) through binding of HIF-1alpha to arrangements of hypoxia response elements. CD is a prodrug activation enzyme, which converts inactive 5-fluorocytosine to active 5-fluorouracil (5-FU), allowing selective killing of vector containing cells.
Laure Marignol, Ruth Foley, Thomas Southgate, Mary Coffey, Donal Hollywood and Mark Lawler
Download Paper
Radiation Therapy Induces Macrophages to Suppress Immune Responses Against Pancreatic Tumors in Mice.
The role of radiation therapy in the treatment of patients with pancreatic ductal adenocarcinoma (PDA) is controversial. Randomized controlled trials investigating the efficacy of radiation therapy in patients with locally advanced unresectable PDA have reported mixed results, with effects ranging from modest benefit to worse outcomes compared with control therapies. We investigated whether radiation causes inflammatory cells to acquire an immune-suppressive phenotype that limits the therapeutic effects of radiation on invasive PDAs and accelerates progression of preinvasive foci.
Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S, Alqunaibit D, Avanzi A, Daley D, Barilla R, Tippens D, Torres-Hernandez A, Hundeyin M, Mani VR, Hajdu C, Pellicciotta I, Oh P, Du K, Miller G.
Download Paper
A preclinical murine model for the early detection of radiation-induced brain injury using magnetic resonance imaging and behavioral tests for learning and memory: with applications for the evaluation of possible stem cell imaging agents and therapies.
Stem cell therapies are being developed for radiotherapy-induced brain injuries (RIBI). Magnetic resonance imaging (MRI) offers advantages for imaging transplanted stem cells. However, most MRI cell-tracking techniques employ superparamagnetic iron oxide particles (SPIOs), which are difficult to distinguish from hemorrhage. In current preclinical RIBI models, hemorrhage occurs concurrently with other injury markers. This makes the evaluation of the recruitment of transplanted SPIO-labeled stem cells to injury sites difficult. Here, we developed a RIBI model, with early injury markers reflective of hippocampal dysfunction, which can be detected noninvasively with MRI and behavioral tests. Lesions were generated by sub-hemispheric irradiation of mouse hippocampi with single X-ray beams of 80 Gy. Lesion formation was monitored with anatomical and contrast-enhanced MRI and changes in memory and learning were assessed with fear-conditioning tests. Early injury markers were detected 2 weeks after irradiation. These included an increase in the permeability of the blood-brain barrier, demonstrated by a 92 ± 20 % contrast enhancement of the irradiated versus the non-irradiated brain hemispheres, within 15 min of the administration of an MRI contrast agent. A change in short-term memory was also detected, as demonstrated by a 40.88 ± 5.03 % decrease in the freezing time measured during the short-term memory context test at this time point, compared to that before irradiation. SPIO-labeled stem cells transplanted contralateral to the lesion migrated toward the lesion at this time point. No hemorrhage was detected up to 10 weeks after irradiation. This model can be used to evaluate SPIO-based stem cell-tracking agents, short-term.
Ngen EJ, Wang L, Gandhi N, Kato Y, Armour M, Zhu W, Wong J, Gabrielson KL, Artemov D.
Download Paper
Xstrahl introduces xbridge to the european market at estro 2016
Xstrahl Medical (Booth 6300) will introduce the next generation in 3rd party connectivity for Xstrahl systems at ESTRO35 in Turin, Italy on Saturday 30th April. XBridge offers Xstrahl users the ability to communicate with 3rd party clinical information systems, enabling data import of patient demographics and export of treatment information, ensuring traceability throughout a patient’s treatment.
Xstrahl Life Sciences at AACR 2016
What could you do with a SARRP? Take a look at some of the amazing research being presented at AACR 2016 with the help of this cutting edge equipment.
Xstrahl showcases the latest research being undertaken using SARRP and the range of Xstrahl Life Science products at ESTRO 2016
Xstrahl Life Sciences will be showcasing the recent developments for SARRP at ESTRO35 in Turin, Italy on Saturday 30th April. The Xstrahl booth (6300) will allow attendees to learn about how cancer research is being enhanced by the Xstrahl SARRP Image Guided Micro-Irradiator. A number of posters and presentations are being given at ESTRO35 that were developed with the help of Xstrahl Life Sciences products.